Hal Barron’s GSK team continues to cull respiratory drugs in big shift to oncology R&D
The new R&D team under Hal Barron is continuing to hack away at its respiratory pipeline.
The pharma giant today sounded taps for six of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
